Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

intervet international b.v.* - benzylpenicillinprocainum; dihydrostreptomycinum súlfat - stungulyf, dreifa

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

boehringer ingelheim animal health nordics a/s - benzylpenicillinprocainum; dihydrostreptomycinum súlfat - stungulyf, dreifa

Evrópusambandið - íslenska - EMA (European Medicines Agency)

pfizer europe ma eeig - pemetrexed disodium, pemetrexed disodium hemipentahydrate - carcinoma, non-small-cell lung; mesothelioma - Æxlishemjandi lyf - malignant pleural mesotheliomapemetrexed pfizer in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancerpemetrexed pfizer in combination with cisplatin is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed pfizer is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy. pemetrexed pfizer is indicated as monotherapy for the second-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

baxter holding b.v. - pemetrexed disodium heptahydrate - carcinoma, non-small-cell lung; mesothelioma - Æxlishemjandi lyf - malignant pleural mesotheliomapemetrexed baxter in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancerpemetrexed baxter in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5. pemetrexed baxter is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see section 5. pemetrexed baxter is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

dechra regulatory b.v. - amoxicillinum tríhýdrat; acidum clavulanicum kalíum - tafla - 40 mg/10 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

williams & halls ehf. - amoxicillinum tríhýdrat; acidum clavulanicum kalíum - filmuhúðuð tafla - 500/125 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

williams & halls ehf. - acidum clavulanicum kalíum; amoxicillinum tríhýdrat - filmuhúðuð tafla - 875/125 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

laboratoires thea* - cefuroximum natríum - stungulyfsstofn, lausn - 50 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

dechra regulatory b.v. - amoxicillinum tríhýdrat; acidum clavulanicum kalíum - tafla - 200 mg/50 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

navamedic asa - cefuroximum natríum - stungulyfsstofn, lausn/dreifa - 250 mg